NCT04454658 2025-07-16
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Active not recruiting
Clinical Trials
22 trialsNCT04472598 2025-02-21
TRANSFORM-1
AbbVie
Phase 3 Completed
NCT00788684 2025-02-20
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
Phase 1 Completed
NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting
NCT03592576 2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available
NCT04480086 2023-08-29
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
AbbVie
Phase 1 Terminated
NCT00481091 2023-06-13
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1/2 Completed
NCT03181126 2021-10-14
A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
AbbVie
Phase 1 Completed
NCT00406809 2021-08-02
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
AbbVie
Phase 1/2 Completed
NCT00445198 2018-06-06
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
AbbVie
Phase 1/2 Completed
NCT00878449 2018-06-06
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
AbbVie
Phase 1 Completed
NCT00887757 2017-11-21
Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00891605 2017-11-21
Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00982566 2017-11-21
Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
AbbVie
Phase 1 Completed
NCT01121133 2017-11-21
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
AbbVie
Phase 1 Completed
NCT01009073 2017-11-20
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
AbbVie
Phase 1 Completed
NCT01087151 2016-11-02
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 2 Completed
NCT01423539 2016-11-02
NAVIGATE
Genentech, Inc.
Phase 2 Withdrawn
NCT00868413 2013-06-07
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
AbbVie
Phase 1 Completed
NCT00888108 2012-05-22
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
Abbott
Phase 1 Completed
NCT01021358 2010-12-20
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
Abbott
Phase 1 Completed
NCT00743028 2010-10-07
Assess the Oral Bioavailability of New ABT-263 Formulations
Abbott
Phase 1 Completed